Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis

(2016) Luca Prosperini et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Reporting treatment outcomes in observational data: A fine balance

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

(2016) Nils Koch-Henriksen et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Comparative efficacy of fingolimod vs natalizumab

(2016) Laetitia Barbin et al.   NEUROLOGY

Reporting treatment outcomes in observational data: A fine balance

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod

(2016) Nils Koch-Henriksen et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials

(2015) A. Signori et al.   EUROPEAN JOURNAL OF NEUROLOGY

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

(2015) Stefan Braune et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis—a quiet revolution

(2015) Richard M. Ransohoff et al.   Nature Reviews Neurology

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

(2015) Anna He et al.   JAMA Neurology

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis

(2014) L. Prosperini et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort

(2013) Stefan Braune et al.   JOURNAL OF NEUROLOGY

Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients

(2013) Massimo Filippi et al.   NEUROLOGICAL SCIENCES

Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic

(2012) Ebru Erbayat Altay et al.   JAMA Neurology

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

(2011) Luca Prosperini et al.   BMC Neurology

The changing face of multiple sclerosis clinical trial populations

(2011) Bernard M.J. Uitdehaag et al.   CURRENT MEDICAL RESEARCH AND OPINION

Review of methodological issues of clinical trials in multiple sclerosis

(2011) Xavier Montalban   JOURNAL OF THE NEUROLOGICAL SCIENCES

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis

(2011) J Theodore Phillips et al.   Multiple Sclerosis Journal

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis

(2011) Luca Prosperini et al.   Multiple Sclerosis Journal

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society

(2011) A. Ghezzi et al.   NEUROLOGICAL SCIENCES

Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic “matrix design”

(2011) Jeremy A. Rassen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina

(2008) A. Carrá et al.   EUROPEAN JOURNAL OF NEUROLOGY